The costs associated with ankylosing spondylitis/axial spondyloarthritis in Aotearoa/New Zealand

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author White, Douglas en
dc.contributor.author Lao, C en
dc.contributor.author Williams, M en
dc.contributor.author Lawrenson, R en
dc.contributor.author Dalbeth, Nicola en
dc.date.accessioned 2020-01-23T02:00:45Z en
dc.date.issued 2019-11-29 en
dc.identifier.citation New Zealand Medical Journal 132(1506):10-19 29 Nov 2019 en
dc.identifier.issn 0028-8446 en
dc.identifier.uri http://hdl.handle.net/2292/49693 en
dc.description.abstract Aim To evaluate costs associated with a diagnosis of spondyloarthritis (SpA) in an Aotearoa/New Zealand cohort. Method Patients with SpA attending specialist SpA clinics in Auckland and Hamilton completed a series of questionnaires on costs associated with ankylosing spondylitis, disease parameters (BASDAI), work productivity (WPAI, WLQ) and quality of life measures (EQ-5D, ASAS-HI). Results Eighty-one patients (median age 43 years) completed the study. All fulfilled the ASAS criteria for axial spondyloarthritis and 44 (58%) fulfilled the Modified New York Criteria for ankylosing spondylitis. The mean (SD) score on the EQ-VAS was 69mm (24.1). More than half reported difficulties with usual activities and more than 80% had moderate pain or discomfort despite current treatment. Sixty-six (82%) were in the workforce, and the mean work productivity loss was 4.8%. The mean (SD) annual cost was NZ$15,677 (NZ$11,269) with NZ$12,189 direct cost and NZ$3,488 productivity loss. The largest cost driver was use of biologic medications, which were used by 48% patients. Conclusion This study has quantified the direct and indirect costs of spondyloarthritis (SpA) in Aotearoa/New Zealand, and demonstrates meaningful reduction in quality of life and work productivity in patients with SpA. The major driver of direct costs in SpA are biologic medications. en
dc.language English en
dc.publisher New Zealand Medical Association en
dc.relation.ispartofseries New Zealand Medical Journal en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.rights.uri https://www.nzma.org.nz/journal/contribute/articles en
dc.subject Science & Technology en
dc.subject Life Sciences & Biomedicine en
dc.subject Medicine, General & Internal en
dc.subject General & Internal Medicine en
dc.subject HEALTH-CARE COSTS en
dc.subject QUALITY-OF-LIFE en
dc.subject RHEUMATOID-ARTHRITIS en
dc.subject PSORIATIC-ARTHRITIS en
dc.subject PRODUCTIVITY en
dc.subject ILLNESS en
dc.subject INDEX en
dc.title The costs associated with ankylosing spondylitis/axial spondyloarthritis in Aotearoa/New Zealand en
dc.type Journal Article en
pubs.issue 1506 en
pubs.begin-page 10 en
pubs.volume 132 en
dc.rights.holder Copyright: NZMA en
pubs.author-url https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2019/vol-132-no-1506-29-november-2019/8054 en
pubs.end-page 19 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Article en
pubs.elements-id 789050 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Medicine Department en
dc.identifier.eissn 1175-8716 en
pubs.record-created-at-source-date 2020-01-23 en


Full text options

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse